Larimar Therapeutics, Inc. (LRMR)

Sentiment-Signal

24,8

Bearisch

Composite Score (0–100)

Insider (25%)

51.5

1 Insider, 25,0M $ Volumen

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
27.01.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of

Stammdaten

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Unternehmen & Branche

Name	Larimar Therapeutics, Inc.
Ticker	LRMR
CIK	0001374690
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	375,2 Mio. USD
Beta	1,02
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	-165,673,000		145,842,000	78,085,000
2025-09-30	10-Q	-47,712,000	-0.61	187,350,000	139,038,000
2025-06-30	10-Q	-26,182,000	-0.41	149,988,000	119,854,000
2025-03-31	10-Q	-29,281,000	-0.46	170,175,000	144,271,000
2024-12-31	10-K	-80,604,000	-1.32	200,225,000	171,812,000
2024-09-30	10-Q	-15,499,000	-0.24	219,021,000	198,400,000
2024-06-30	10-Q	-21,627,000	-0.34	237,162,000	211,404,000
2024-03-31	10-Q	-14,654,000	-0.27	248,205,000	230,844,000
2023-12-31	10-K	-36,949,000	-0.84	95,935,000	81,720,000
2023-09-30	10-Q	-9,064,000	-0.21	103,952,000	92,712,000
2023-06-30	10-Q	-8,366,000	-0.19	111,716,000	99,930,000
2023-03-31	10-Q	-6,526,000	-0.15	118,907,000	106,241,000
2022-12-31	10-K	-35,355,000	-1.37	126,405,000	110,903,000
2022-09-30	10-Q	-8,320,000	-0.37	133,015,000	118,662,000
2022-06-30	10-Q	-8,667,000	-0.47	62,852,000	50,056,000
2022-03-31	10-Q	-8,943,000	-0.49	71,223,000	57,105,000
2021-12-31	10-K	-50,636,000	-2.95	78,667,000	64,413,000
2021-09-30	10-Q	-16,805,000	-0.92	87,938,000	72,067,000
2021-06-30	10-Q	-12,609,000	-0.79	80,931,000	67,525,000
2021-03-31	10-Q	-12,088,000	-0.76	93,019,000	78,784,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-02-27	Flynn James E	Director, 10% Owner	Open Market Purchase	2,000,000	5.00	10,000,000.00	+163,5%
2026-02-27	Flynn James E	Director, 10% Owner	Open Market Purchase	831,978	5.00	4,159,890.00	+68,0%
2026-02-27	Flynn James E	Director, 10% Owner	Open Market Purchase	1,084,010	5.00	5,420,050.00	+88,6%
2026-02-27	Flynn James E	Director, 10% Owner	Open Market Purchase	1,084,012	5.00	5,420,060.00	+88,6%
2026-02-27	THOMAS FRANK E	Director	Open Market Purchase	5,000	5.00	25,000.00	+0,4%
2026-02-27	SHERMAN JEFFREY W	Director	Open Market Purchase	5,000	5.00	25,000.00	+0,4%
2025-07-31	Flynn James E	Director, 10% Owner	Open Market Purchase	3,387,529	3.20	10,840,092.80	+177,2%
2025-07-31	Flynn James E	Director, 10% Owner	Open Market Purchase	3,387,539	3.20	10,840,124.80	+177,2%
2025-07-31	Flynn James E	Director, 10% Owner	Open Market Purchase	2,599,932	3.20	8,319,782.40	+136,0%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.